IN THE CLAIMS

Please cancel claims 31, 38, and 43 without prejudice, amend the claims, and add new claims 50-52, as follows:

30. (Currently Amended) A compound of the general formula:





---

having the (3S,4S) configuration, and which is essentially free of the (3R,4R) enantiomer, wherein:

A---B designates an optional double bond,

R_1 is -R'OR''' wherein R' is C_1-C_5 straight or branched chain alkyl and R''' is hydrogen or C_1-C_5 alkyl;

G is $-OR_2$ wherein R_2 is C_1-C_5 straight or branched chain alkyl; and

R_3 is a straight chain or branched -C_5-C_{12} alkyl~~C_1-C_{12} straight or branched chain alkyl~~.

31. (Cancelled).

32. (Previously Presented) The compound of claim 30, wherein R_3 is 1,1-dimethyl heptyl or 1,2-dimethyl heptyl.

33. (Previously Presented) The compound of claim 30, wherein R_1 is $-CH_2OH$, G is $-OCH_3$, and R_3 is 1,1-dimethyl heptyl.

34. (Previously Presented) The compound of claim 33, wherein the dotted line represents a double bond.

35. (Previously Presented) A pharmaceutical composition for preventing the symptoms of, treating, or managing hypertension, inflammation, peripheral pain, gastrointestinal disorders, or autoimmune diseases comprising as an active ingredient a therapeutically effective amount of a compound of claim 30.

36. (Previously Presented) The pharmaceutical composition of claim 35 further comprising a pharmaceutically acceptable diluent or carrier.

37. (Previously Presented) The pharmaceutical composition of claim 36, wherein the diluent is an aqueous cosolvent solution comprising a pharmaceutically acceptable cosolvent, a micellar solution or emulsion prepared with natural or synthetic ionic or non-ionic surfactants, or a combination of such cosolvent and micellar or emulsion solutions.

38. (Cancelled).

39. (Previously Presented) The pharmaceutical composition of claim 35, wherein R_3 is 1,1-dimethyl heptyl or 1,2-dimethyl heptyl.

40. (Previously Presented) The pharmaceutical composition of claim 35, wherein R_1 is $-CH_2OH$, G is $-OCH_3$, and R_3 is 1,1-dimethyl heptyl.

41. (Previously Presented) The pharmaceutical composition of claim 40, wherein the dotted line represents a double bond.

42. (Currently Amended) A CB2 specific agonist comprising a compound of the general formula:





---

having the (3S,4S) configuration, and which is essentially free of the (3R,4R) enantiomer, wherein:

A---B designates an optional double bond,

R_1 is -R'OR''' wherein R' is C_1-C_5 straight or branched chain alkyl and R''' is hydrogen or C_1-C_5 alkyl;

G is -OR_2 wherein R_2 is C_1-C_5 straight or branched chain alkyl; and

R_3 is a straight chain or branched -C_5-C_{12} alkyl~~C_1-C_{12} straight or branched chain alkyl~~.

43. (Cancelled).

44. (Previously Presented) The agonist of claim 42, wherein R_3 is 1,1-dimethyl heptyl or 1,2-dimethyl heptyl.

45. (Previously Presented) The agonist of claim 42, wherein R_1 is $-CH_2OH$, G is $-OCH_3$, and R_3 is 1,1-dimethyl heptyl.

46. (Previously Presented) The agonist of claim 45, wherein the dotted line represents a double bond.

47. (Currently Amended) A pharmaceutical composition for preventing the symptoms of, treating, or managing hypertension, inflammation, peripheral pain, gastrointestinal disorders, or autoimmune diseases comprising as an active ingredient a therapeutically effective amount of the CB2 specific agonist of claim 42~~claim 40~~.

48. (Previously Presented) The pharmaceutical composition of claim 47, further comprising a pharmaceutically acceptable diluent or carrier.

49. (Previously Presented) The pharmaceutical composition of claim 48, wherein the diluent is an aqueous cosolvent solution comprising a pharmaceutically acceptable cosolvent, a micellar solution or emulsion prepared with natural or synthetic ionic or non-ionic surfactants, or a combination of such cosolvent and micellar or emulsion solutions.

50. (New) The pharmaceutical composition of claim 47, wherein R_3 is 1,1-dimethyl heptyl or 1,2-dimethyl heptyl.

51. (New) The pharmaceutical composition of claim 47, wherein R_1 is $-CH_2OH$, G is $-OCH_3$, and R_3 is 1,1-dimethyl heptyl.

52. (New) The pharmaceutical composition of claim 47, wherein the dotted line represents a double bond.